Alzamend Neuro partners with Mass General for a Phase 2 clinical trial comparing its Alzheimer's treatment AL001 with lithium salt.
Alzamend Neuro partners with Mass General Hospital for a Phase 2 clinical trial, comparing its potential Alzheimer's treatment AL001 with a common lithium salt. The study aims to assess increased brain lithium levels in Alzheimer's patients and healthy subjects, to determine the minimum dose for equivalent effectiveness and safety. This could lead to a next-generation lithium product with improved safety and brain distribution.
August 05, 2024
3 Articles